BrightSpring Health Services has reported that its recently integrated Amedisys and LHC Group assets outperformed initial performance metrics during the second quarter, driving approximately $78 million in revenue and $8 million in adjusted EBITDA, according to corporate financial disclosures. Leadership attributes the early financial outperformance to stronger-than-expected patient volume growth across acquired branches following the completion of the major home health and hospice transactions.
Speaking on the company’s second-quarter earnings call, Chief Financial Officer Jennifer Phipps detailed the deliberate strategy behind the initial integration timeline. From a guidance perspective, the company had originally planned for a slower ramp-up on several growth initiatives to ensure internal teams possessed adequate time to execute complex operational integrations. With those structural hurdles largely resolved, executive leadership expressed increased confidence in upgrading forward-looking financial targets for the remainder of the fiscal year.
The Louisville, Kentucky-based provider operates an extensive national network spanning home- and community-based health services alongside pharmacy operations. The corporate restructuring follows a May 2025 divestiture agreement in which Amedisys struck a formal deal with the Pennant Group and BrightSpring to offload specific home health and hospice centers as part of its broader merger integration with UnitedHealth Group. These strategic portfolio adjustments have rapidly transformed BrightSpring’s balance sheet and operational footprint across the United States healthcare sector.
Financial Performance and Acquisition Guidance
During the earnings briefing, Chief Executive Officer Jon Rousseau outlined upwardly revised forecasts tied directly to the corporate buyouts. BrightSpring now anticipates that the acquired Amedisys and LHC Group assets will contribute $35 million in EBITDA through 2026, marking a $5 million lift over projections shared previously during the first-quarter earnings call. This continuous expansion powered total enterprise revenue for the second quarter to $3.9 billion, representing a 23% increase compared to the same period in the previous year.
The company’s home health segment established itself as the fastest-growing provider service line, generating $278 million in quarterly revenue. This figure reflects a 51% surge year-over-year. Rousseau noted that the impressive gains were propelled by accelerated average daily census growth, deliberate de novo geographic expansions, and the immediate revenue impact generated by the newly integrated Amedisys and LHC asset portfolio.
Beyond major transactions, BrightSpring continues to target smaller, strategic footprint extensions. Rousseau confirmed that the organization successfully executed several compact tuck-in deals and localized geographic expansions during the second quarter, maintaining active optimism regarding the finalization of these supplementary agreements throughout the second half of 2026.
Meanwhile, the company’s personal care service line delivered $107 million in second-quarter revenue, marking a 7% year-over-year climb. Phipps pointed to modest gains in total persons served, robust increases in total billable hours, and steady operational consistency as the primary drivers behind the personal care division’s steady performance.
Market Expansion and Technological Integration
Looking toward broader market opportunities, Rousseau identified the home infusion sector as a prime growth frontier. Describing the market as heavily fragmented, leadership estimates that the home infusion landscape represents an addressable $20 billion commercial opportunity for scaled operators positioned to capture complex clinical referrals.
To support this rapid scaling, BrightSpring is actively overhauling its technological infrastructure and workforce management systems. The enterprise has committed capital toward advanced clinical, human resources, and operational platforms, deploying artificial intelligence tools and automated agents across daily workflows. Rousseau explained that these technologies are now embedded into recruitment, onboarding, patient intake, documentation reviews, medication reconciliations, and personalized patient care planning.
Phipps indicated that tangible financial and operational returns from these artificial intelligence and automation investments are expected to materialize visibly either later in 2026 or early in 2027. In tandem with software upgrades, the enterprise has onboarded specialized executive talent designed to maximize administrative efficiency and clinical value.
On the reimbursement and contracting front, Rousseau highlighted that sustained clinical quality performance and robust collaborative relationships with insurance payers, accountable care organizations, and hospital systems have positioned BrightSpring favorably for preferred-provider designations. Leadership intends to capitalize on these institutional ties by formalizing structured post-discharge care pathways, a move expected to secure additional referral volume as integration milestones conclude.
Related reading